Subtype
Skin Squamous Cell Carcinoma
CI-CAN-00003959Explore in graph →
89 active trials1 approved drugs3 evidence items
- NCIt
- C4819
- OncoTree
- CSCC
- DOID
- 3151
- UMLS CUI
- C0553723
- MeSH
- D000099314
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003959Explore in graph →
Clinical trials
211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (39)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04870840 | Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer | completed | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT06610071 | NIFR Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose SWIG Technique(NIFR;SWIG) | not yet recruiting | Phase 1 | 592 | The Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeOTHER | 0 | Sep 24, 2024 | clinicaltrials |
| NCT04160065 | Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers | completed | Phase 1 | 23 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Sep 23, 2024 | clinicaltrials |
| NCT03370861 | How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes(MINING) | terminated | — | 54 | Washington University School of MedicineOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT06577311 | Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) | unknown | Phase 2 | 20 | The Center for Clinical and Cosmetic ResearchOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT04853602 | IFx-Hu2.0 Expanded Access Program | available | — | — | TuHURA Biosciences, Inc.INDUSTRY | 0 | Aug 12, 2024 | clinicaltrials |
| NCT06536946 | B-catenin in Cutaneous Squamous Cell Carcinoma and Its Mimickers | unknown | — | 50 | Sohag UniversityOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04925713 | IFx-Hu2.0 for the Treatment of Patients With Skin Cancer | completed | Phase 1 | 5 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06384820 | Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) | withdrawn | Phase 2 | 0 | Regeneron PharmaceuticalsINDUSTRY | 0 | Jul 26, 2024 | clinicaltrials |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | withdrawn | Phase 2 | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 25, 2024 | clinicaltrials |
| NCT02964559 | Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer | completed | Phase 2 | 11 | Emory UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT04204837 | Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin | recruiting | Phase 2 | 61 | Salzburger LandesklinikenOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT05412875 | Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06342297 | Dermatoscopy Guided Resection for Skin Cancer | unknown | N/A | 400 | Region Örebro CountyOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03590054 | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 35 | Rahul AggarwalOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT02324608 | Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer | completed | N/A | 15 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05490485 | Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma | unknown | Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 8, 2023 | clinicaltrials |
| NCT04362722 | Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients(DUNCAN) | unknown | Phase 2 | 40 | Philogen S.p.A.INDUSTRY | 3 | Oct 10, 2023 | clinicaltrials |
| NCT05845632 | Time to Treatment and Disease-free Survival of Patients With High-risk Head-neck Cutaneous Squamous Cell Carcinoma | unknown | — | 965 | Maastricht University Medical CenterOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT05729139 | Cemiplimab/Peg-Interferon-α in Advanced CSCC | withdrawn | Phase 1 | 0 | Baptist Health South FloridaOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05886140 | Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin | unknown | N/A | 24 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05493826 | Real World Study on the Use of Cemiplimab in Adult Patients in UK(REACT-CEMI) | completed | — | 110 | SanofiINDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04252612 | Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study | withdrawn | Early Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT03982212 | A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors | unknown | Phase 1 | 10 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05220748 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC | withdrawn | Phase 1 | 0 | Rakuten Medical, Inc.INDUSTRY | 0 | Apr 19, 2023 | clinicaltrials |
| NCT04611321 | Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 15 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT04242173 | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | terminated | Phase 2 | 3 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT02218164 | Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 8 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT04985825 | Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma(I-PACE) | withdrawn | Phase 2 | 0 | Pega-One S.A.S.INDUSTRY | 0 | Sep 13, 2022 | clinicaltrials |
| NCT05025813 | Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma(DESQUAMATE) | recruiting | Phase 2 | 27 | Queensland HealthOTHER_GOV | 1 | Aug 1, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05238363 | The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) | unknown | Phase 2 | 20 | Shanghai Henlius BiotechINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04664582 | Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck | unknown | N/A | 100 | Jewish General HospitalOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT05246228 | Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy(HR-cSCC) | unknown | — | 42 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 0 | Feb 18, 2022 | clinicaltrials |
| NCT03291002 | Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC | unknown | Phase 1 | 98 | CureVacINDUSTRY | 5 | Nov 4, 2021 | clinicaltrials |
| NCT03773744 | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma(Pelican) | withdrawn | Phase 1 | 0 | Turnstone Biologics, Corp.INDUSTRY | 0 | Apr 6, 2021 | clinicaltrials |
| NCT03353077 | Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT) | completed | N/A | 28 | Alpha Tau Medical LTD.INDUSTRY | 1 | Mar 10, 2021 | clinicaltrials |
| NCT02347813 | Preventing Squamous Cell Skin Cancer | completed | Phase 2 | 12 | University of RochesterOTHER | 0 | Jun 23, 2020 | clinicaltrials |
| NCT01198028 | Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma | completed | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03834233 | Nivolumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma(CA209-9JC) | unknown | Phase 2 | 24 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Feb 12, 2020 | clinicaltrials |
| NCT00126555 | Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Aug 30, 2019 | clinicaltrials |
| NCT03492489 | Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma | no longer available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Aug 1, 2019 | clinicaltrials |
| NCT01017185 | Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions | completed | Phase 1 | 28 | Takara Bio Inc.INDUSTRY | 1 | May 23, 2019 | clinicaltrials |
| NCT03822988 | ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS(PADAONCODERM) | unknown | — | 150 | Central Hospital, Nancy, FranceOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT01764607 | Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma | terminated | Phase 2 | 1 | University of FloridaOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT03621462 | Elucid Labs AIDA™ - Labelled Image Acquisition Protocol | unknown | N/A | 4,000 | Elucid Labs Inc.INDUSTRY | 1 | Aug 8, 2018 | clinicaltrials |
| NCT01823679 | Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin | terminated | Phase 2 | 2 | Stanford UniversityOTHER | 1 | Apr 12, 2018 | clinicaltrials |
| NCT01984892 | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)(Hiltonol) | terminated | Phase 2 | 8 | Nina BhardwajOTHER | 1 | Jan 23, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Oct 29, 2024source: clinicaltrials